Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Karuna Therapeutics	Arvinas	Alkermes	Pacira BioSciences	Reata Pharmaceuticals
Symbol	NASDAQ:KRTX	NASDAQ:ARVN	NASDAQ:ALKS	NASDAQ:PCRX	NASDAQ:RETA
Price Information
Current Price	$113.83	$66.91	$22.26	$62.21	$78.35
52 Week Range	Buy	Buy	Hold	Buy	Buy
MarketRank™
Overall Score	1.8	1.7	1.2	2.3	1.4
Analysis Score	4.5	4.5	1.0	4.3	3.5
Community Score	3.0	2.4	2.8	2.9	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	1.7	0.0	0.8
Earnings & Valuation Score	0.0	0.0	0.6	4.4	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Buy	Buy
Consensus Price Target	$151.70	$113.15	$22.00	$78.58	$227.13
% Upside from Price Target	33.27% upside	69.11% upside	-1.17% downside	26.32% upside	189.89% upside
Trade Information
Market Cap	$3.35 billion	$3.28 billion	$3.57 billion	$2.74 billion	$2.84 billion
Beta	2.07	2.14	1.25	1.27	1.57
Average Volume	189,543	450,235	1,388,440	486,676	307,438
Sales & Book Value
Annual Revenue	N/A	$42.98 million	$1.17 billion	$421.03 million	$26.52 million
Price / Sales	N/A	76.26	3.05	6.50	106.95
Cashflow	N/A	N/A	$0.59 per share	$1.46 per share	N/A
Price / Cash	N/A	N/A	37.52	42.56	N/A
Book Value	$16.65 per share	$6.72 per share	$6.89 per share	$8.51 per share	$7.74 per share
Price / Book	N/A	9.96	3.23	7.31	10.12
Profitability
Net Income	$-43,960,000.00	$-70,290,000.00	$-196,620,000.00	$-11,020,000.00	$-290,170,000.00
EPS	($3.68)	($2.13)	$0.07	$0.86	($9.54)
Trailing P/E Ratio	N/A	N/A	N/A	21.90	N/A
Forward P/E Ratio	N/A	N/A	318.00	21.60	N/A
P/E Growth	N/A	N/A	12.74	0.82	N/A
Net Margins	N/A	-403.77%	-6.28%	29.95%	-4,340.72%
Return on Equity (ROE)	-13.91%	-46.99%	9.35%	10.71%	-163.42%
Return on Assets (ROA)	-13.72%	-35.34%	5.50%	4.88%	-56.49%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.01%	0.25%	0.78%	N/A
Current Ratio	70.57%	6.53%	2.71%	7.63%	12.98%
Quick Ratio	70.56%	6.53%	2.39%	6.84%	12.98%
Ownership Information
Institutional Ownership Percentage	74.83%	75.68%	97.30%	N/A	64.30%
Insider Ownership Percentage	18.10%	10.99%	4.49%	5.80%	31.70%
Miscellaneous
Employees	63	179	2,245	624	261
Shares Outstanding	29.46 million	48.99 million	160.45 million	44.03 million	36.20 million
Next Earnings Date	8/4/2021 (Estimated)	8/3/2021 (Estimated)	8/4/2021 (Estimated)	8/5/2021 (Estimated)	8/9/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Reata Pharmaceuticals (NASDAQ:RETA) Sets New 1-Year Low at $83.51 americanbankingnews.com - May 10 at 2:43 PM
	Reata Pharmaceuticals (NASDAQ:RETA) Issues Earnings Results americanbankingnews.com - May 9 at 3:20 PM
	Brokerages Anticipate Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to Announce -$2.40 Earnings Per Share americanbankingnews.com - May 8 at 1:22 PM
	Reata Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation seekingalpha.com - May 7 at 7:57 PM
	Reata Pharmaceuticals (NASDAQ:RETA) Trading Down 4.8% americanbankingnews.com - May 7 at 1:42 PM
	Reata Pharmaceuticals (NASDAQ:RETA) Now Covered by Analysts at Barclays americanbankingnews.com - May 3 at 10:19 AM
	Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences finance.yahoo.com - May 3 at 9:29 AM
	Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q1 Earnings Expected to Decline finance.yahoo.com - April 29 at 8:20 PM
	Reata Pharmaceuticals (RETA) Scheduled to Post Earnings on Thursday americanbankingnews.com - April 29 at 8:36 AM
	Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients ... apnews.com - April 27 at 9:47 AM
	WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas feeds.benzinga.com - April 27 at 7:40 AM
	Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome finance.yahoo.com - April 26 at 6:41 PM
	Reata Pharmaceuticals (NASDAQ:RETA) Trading Up 9.4% americanbankingnews.com - April 26 at 1:46 PM
	Is RETA Stock A Buy or Sell? finance.yahoo.com - April 26 at 1:40 PM
	A Buy the Dip Stock Trigger in Reata Pharmaceuticals Inc cmlviz.com - April 22 at 6:52 AM
	Financial Contrast: Reata Pharmaceuticals (NASDAQ:RETA) versus Immuron (NASDAQ:IMRN) americanbankingnews.com - April 22 at 4:24 AM
	Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences finance.yahoo.com - March 29 at 8:58 PM
	Reata Pharmaceuticals Stock Shows Every Sign Of Being Significantly Overvalued finance.yahoo.com - March 29 at 3:13 PM
	Reata Pharmaceuticals, Inc. Submits NDA for Company's Lead Program: Bardoxolone in Alport Syndrome benzinga.com - March 3 at 8:03 AM
	Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and ... apnews.com - March 2 at 9:53 AM
	Reata Pharma Shares Are Trading Higher After Filing US Application In Alport Syndrome-Related Kidney Disease finance.yahoo.com - March 1 at 6:05 PM
	Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome finance.yahoo.com - March 1 at 7:28 AM
	Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome finance.yahoo.com - March 1 at 7:28 AM
	Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs finance.yahoo.com - March 1 at 7:28 AM
	Reata Pharmaceuticals Alpha (5Y) ycharts.com - February 19 at 5:41 PM

Date	Company	Brokerage	Action
5/13/2021	Karuna Therapeutics	The Goldman Sachs Group	Lower Price Target
5/3/2021	Karuna Therapeutics	HC Wainwright	Boost Price Target
3/29/2021	Karuna Therapeutics	Bank of America	Initiated Coverage
3/8/2021	Karuna Therapeutics	Oppenheimer	Boost Price Target
3/4/2021	Karuna Therapeutics	JMP Securities	Boost Price Target
3/4/2021	Karuna Therapeutics	Mizuho	Boost Price Target
2/26/2021	Karuna Therapeutics	Maxim Group	Reiterated Rating
2/9/2021	Karuna Therapeutics	Royal Bank of Canada	Initiated Coverage
1/5/2021	Karuna Therapeutics	William Blair	Reiterated Rating
6/3/2020	Karuna Therapeutics	Stifel Nicolaus	Boost Price Target
4/27/2021	Arvinas	Truist Securities	Initiated Coverage
4/21/2021	Arvinas	Northern Trust Capital Markets	Initiated Coverage
3/31/2021	Arvinas	BMO Capital Markets	Initiated Coverage
3/30/2021	Arvinas	Cantor Fitzgerald	Boost Price Target
12/21/2020	Arvinas	Piper Sandler	Boost Price Target
12/15/2020	Arvinas	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
12/15/2020	Arvinas	Smith Barney Citigroup	Boost Price Target
12/15/2020	Arvinas	Roth Capital	Boost Price Target
12/14/2020	Arvinas	Wedbush	Boost Price Target
12/11/2020	Alkermes	SVB Leerink	Boost Price Target
10/7/2020	Alkermes	JPMorgan Chase & Co.	Reiterated Rating
4/2/2020	Alkermes	Morgan Stanley	Lower Price Target
2/14/2020	Alkermes	Cowen	Reiterated Rating
5/11/2021	Pacira BioSciences	Northland Securities	Lower Price Target
4/15/2021	Pacira BioSciences	Berenberg Bank	Initiated Coverage
2/26/2021	Pacira BioSciences	Barclays	Boost Price Target
1/8/2021	Pacira BioSciences	Needham & Company LLC	Boost Price Target
9/30/2020	Pacira BioSciences	Jefferies Financial Group	Boost Price Target
6/16/2020	Reata Pharmaceuticals	BTIG Research	Initiated Coverage
6/12/2020	Reata Pharmaceuticals	Robert W. Baird	Reiterated Rating
11/13/2019	Reata Pharmaceuticals	National Securities	Downgrade

(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources